Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Richard A Messmann, MD, MHS, MSc
Endocyte
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Horizon Oncology Center
Lafayette, Indiana, United States
- Greenebaum Cancer Center - University of Maryland
Baltimore, Maryland, United States
- Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
- Barbara Ann Karmanos Cancer Institute - Wayne State University
Detroit, Michigan, United States
- Great Lakes Cancer Institute - Michigan State University
Lansing, Michigan, United States
- Providence Cancer Institute
Southfield, Michigan, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2009
- Primary completion
- 31 Dec 2011
- Completion
- 30 Apr 2012
- Last update posted
- 8 Aug 2012
- Registered enrollment
- 65
- Registry id
- NCT00852189
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.